Ottawa Hematology BioBank



Founded in 2009, The Ottawa Hospital’s Hematology BioBank stores tissue samples from patients seen in the Division of Hematology for a variety of conditions. Samples collected include: peripheral blood (buffy coat and plasma), buccal swab and bone marrow. The samples are processed, bar code-labeled (de-identified) and stored in vapour-phase liquid nitrogen at the Biorepository, Civic Campus, of The Ottawa Hospital.

Available Samples

All BioBank samples are available for purchase with the provision of an REB approved protocol (OHSN-REB). Samples are provided with a database including demographic, clinical and treatment details. Researchers within The Ottawa hospital have the option for fresh samples to be delivered to their lab for testing. Frozen samples can be shipped across Canada.

We encourage requests for sample types and conditions not currently stored to be made with the coordinator. Prospective sample collection is available to researchers year-round.


Please contact the coordinator at: for a detailed quote.

Sample Catalogue

A summary of the inventory as of August 2018 by donor and type

Total Donors 2895
Acute Lymphoblastic Leukemia (ALL) 93
Acute Myeloid Leukemia (AML) 466
Chronic lymphocytic leukemia (CLL) 478
Chronic myeloid leukemia (CML) 64
Leukemia NOS 13
Hodgkin’s Lymphoma 90
Non-Hodgkins Lymphoma 478
Aplastic Anemia 21
Myelodysplastic Syndrome (MDS) 251
Myeloma/MGUS 178
Myeloproliferative disorders 76
Non-malignant 33
Healthy Samples 34
Other 120
Study (CONSKP) 500

Total Samples 30146
Buccal 2885
BMA 4273
Plasma 8067
Buffy 7206
Serum 5649
Whole 2066

Current projects

  1. The role of PCL2 in regulating gene expression and proliferation in-vitro. Principle Investigators: Dr. Stanford & Dr. Sabloff, The Ottawa Hospital
  2. Investigation of the role of bone marrow for the development of novel long lasting natural killer cells expanded during cytomegalovirus infection. Principle Investigators: Dr. Lee & Dr. Cowan, The Ottawa Hospital
  3. Capacity building for immunotherapy in Ottawa. Principle Investigator: Dr. Kekre, The Ottawa Hospital
  4. Feasibility and validation study of the LSC17 score in Acute Myeloid Leukemia patients. Principle Investigator: Dr. Steven Chan, UHN


  1. Maganti HB, Jrade H, Cafariello C, Manias Rothberg JL, Porter CJ, Yockell-Lelièvre J et al. Targeting the MTF2-MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy. Cancer Discov 2018; : CD-17-0841.
  2. Boyd AL, Reid JC, Salci KR, Aslostovar L, Benoit YD, Shapovalova Z et al. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nat Cell Biol 2017; 19: 1336–1347.
  3. Chandran P, Le Y, Li Y, Sabloff M, Mehic J, Rosu-Myles M et al. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leuk Res 2015; 39: 486–493.
  4. Le Y, Fraineau S, Chandran P, Sabloff M, Brand M, Lavoie JR et al. Adipogenic Mesenchymal Stromal Cells from Bone Marrow and Their Hematopoietic Supportive Role: Towards Understanding the Permissive Marrow Microenvironment in Acute Myeloid Leukemia. Stem Cell Rev Reports 2016; 12: 235–244.
  5. Chmara J, Browning JWL, Atkins H, Sabloff M, McKay BC. Rapid Decrease in KRT14 and TP53 mRNA Expression in the Buccal Mucosa of Patients Receiving Total-Body Irradiation for Allogeneic Stem Cell Transplantation. Radiat Res 2018; 189: 213–218.